-
example of synergy
penicillin & aminoglycosides for endocarditis
-
time dependent killers
- 1) PCN
- 2) CEPHS
- 3) Carbapenems
- 4) Vancomycin
-
Concentration Dependent Killers
- 1) FQs
- 2) AMGs
- 3) Daptomycin
- 4) Telithromycin
-
DI w/ warfarin
May increase INR (vitamin K absorption in gut)
-
DI Antacids/cations
inhibit ABX absorption - esp FQs - 2 hrs B4, 4 hrs after
-
DI: CYP450 interactions
- 1) Cipro (1A2 inh)
- 2) Erythro (1A2 & 3A4 Inh)
- 3) Quin/Dalfo (3A4 inh)
- 4) Telithromycin (3A4 inh)
-
-
Penicillin MOA
Inhibit bacterial cell wall synthesis - B Lactam antibiotics
-
Penicillin ex & pen
- 1) ex - primarily kidneys (ex naf & oxa)
- 2) pen - good - lung, liver, kidney, muscle, bone
-
Penicillins SE:
- 1) Diarrhea
- 2) Rash
- 3) Fever
- 4) Neutropenia
- 5) Thrombocytopenia
- 6) Seizures
-
Nafacillin and Oxacillin - warning & elimination
- 1) High Na+ in IV form - watch in pts with HTN
- 2) Hepatically eliminated, no renal adj.
-
Amino PCNS -
Ampicillin, Amoxicillin, Bacampicillin
-
Antipsuedomonal PCNs
- (Carboxypenicillins, Ureidopenicillins)
- Piperacillin,
- Ticarcillin
-
AB Lactamase Inhibitor PCNS: Agents
- 1) Augmentin PO (Amox/Clavulanate)
- 2) Timetin IV (Ticarcillin/Clavulanate)
- 3) Zosyn IV (Piperacilli/nzobactam)
- 4) Unasyn IV (Ampicillin/Sulbactam)
-
Cephalosporins MOA, Excretion, SE
- Inhibit bacterial cell wall synthesis
- - renal excretion
- - GI, rash, neutropenia, seizures
-
1st generation cephalosporins
- 1) Cefazolin
- 2) Cephalexin (PO)
- 3) Cefaclor
- 4) Cefadroxil
-
2nd generation cephalosporins
- Cefuroxime (IV, PO)
- Cefotetan
- Cefoxitin
- Cefprozil (PO)
-
2nd generation coverage
1) Gram (+) - >60%: Strep: Pneumo, ABCG, viridans, MSSA -30-60%: Staph epidermidis 2) Gram - >60%: Proteus, E. Coli, Klebsiella, Moraxella, Neisseria gonorrheae, H. Influenzae, Serratia (cefotetan only) - 30-60%: Citrobacter, Enterobacter (not cefoxitin Cefotetan/Cefoxitin: anaerobic coverage - >60%: Clostridium (not difficile), B. fragilis
-
3rd Generation Cephalosporins
- IV: Ceftriaxone, Ceftazidime, Cefotaxime
- PO: Cefpodoxime, Cefixime, Cefdinir, Ceftobiprole
-
Carbepenam MOA
Lysis of bacterial cell wall - only IV
-
carbapenams have PAE vs
gram - bugs
-
carbapenam elimination
renal - may require adjustment
-
-
Meropenam and Doripenman
QID & TID dosing
-
Monobactams: Aztreonam - MOA & coverage
inhibit bacterial cell wall synthesis - gram - only - covers psuedomonas
-
Gycopeptides
- Vacomycin
- Teicoplanin
- Televancin
-
Gycopeptides (Vacomycin, Teicoplanin, Televancin) MOA & Toxicities
Inhibit bacterial cell wall synthesis - 1) Ototoxicity 2) Renal Dysfunction (trough 5-15 mg/dL)
-
SE of Vanco
Red Man's Syndrome - always infuse vanco over 6- min - less with ticoplanin
-
VRE -use:
- 1) Quinpristin/Dalfopristin (Synercid)
- 2) Linezolid (Zyvox)
-
Floruoquinolone MOA
target bacterial topoisomerases - inhibit bacterial DNA replication - many QD dosing - post antibiotic effect vs gram -
-
Fluoroquinolones SE
- Gi
- - Seuizures
- - Rash
- - Tendon Rupture
- - CNS SE
- - Hyper/Hypoglycemia
- - Photosensitivity
- - QT prolongation
- - Bone Effects: chondrocyte tox, growth in kids, risk vs benefit
-
Oxafloxacin/Norfloxacin
Older, cover primarily gram -
-
Ciprofloxacin
most potent vs pseudomonas - less gram - vs levo/gati
-
Levo/Gemi
new agents - respiratory quinolones - good gram -, some gram + - better coverages vs. strep, H flu, atypic, pseudos
-
Moxifloxacin
like levo/gemi, adds anaerobic coverage
-
Aminoglycosides MOA
inhibit protein synthesis by binding to 30s ribosomal subunit
-
aminoglycoside SE:
- Ototoxicity (irreversible, uncommon)
- - Renal dysf - moon BUN/ Scr, adj dose - goal trough <1mg/dL for QD dosing - neuromuscular block is rare, associated with rapid IV infusion
-
For less nephro with aminoglycosides, use
extended interval dosing - post antibiotic effect against gram -
-
Aminoglycosides: Agents
- - Gentamycin
- - Tobramycin
- - Amikacin
- - Netilmicin
- - Streptomycin
-
Aminos: Primary Coverage
**GRAM -** - Including Pseudomonas - very little gram + - synergy for endocarditis - staph, enterococcus
-
Macrolides MOA
inhibit bacterial protein synthesis - bind to 50s subunit
-
erythromycin
more SE (esp GI) & more DI (cyp1A2 & 3A4 inhibitor)
-
azithro/clarithro
better tolerated - less SE, QD - BID dosing vs QID
-
clarithromycin
needs renal adj at circle <30 ml/min
-
azithromycin
very few clinically significant drug interactions
-
erythro SE
GI upset, rash, LFTs, rare hearing loss
-
clarithro/azithro SE
Gi upset - rare rash, lfts, transit hearing loss
-
macrolides
- erythromycin
- clarithromycin
- azithromycin
-
macrolide primary coverage
**ATYPICALS** clamydia, legionella, mycoplasma - mod gram + & -
-
Ketolides (Telithromycin) - MOA
inh bacterial protein synthesis, bind to 50s subunit - activity against resistant strains
-
ketolides are:
- conc dependent, bactericidal
- - Po formulation
- - many DIs
- - 3A4 inhibitor
-
FDA indication for Telithromycin
community acq pneumonia
-
Telithromycin - adjustments
renal and hepatic
-
telithromycin - adverse effects
Vision problems, di, nausea, dizziness, HA - preg category C
-
Trimethroprim-Sulfamethoxazole (Bactrim, Cotrim, Septra) MOA
each inhibits step in folic acid synthesis - bactericidal - high urinary conc
-
Primary use for Trimethroprim-Sulfamethoxazole (Bactrim, Cotrim, Septra)
UTI, HIV prophylaxis of opportunistic infections
-
Trimethroprim-Sulfamethoxazole (Bactrim, Cotrim, Septra) SE
N/V, di, rash, feer, leuko/thrombo, stevens-johnson syndrome
-
Trimethroprim-Sulfamethoxazole (Bactrim, Cotrim, Septra) DI
bacterium may displace other highly protein bound drugs (warfarin, phenytoin, methotrexate)
-
CI for Trimethroprim-Sulfamethoxazole (Bactrim, Cotrim, Septra)
- Pregnancy (3rd trimester only), severe liver disease
-
Clindamycin & Metronidazole
Grouped together - potent at treating anaerobes
-
Clindamycin MOA
inhibit bacterial protein synthesis
-
CLindamycin SE
GI!!!!!!! - number one cause of C diff - inc LFs, rash
-
Clindamycin DIs
may enhance nm blockade of such agents
-
Clinda also active against
Strep, MSSA
-
Metronidazole MOA
damage bacterial DNA --> bacteriocidal
-
metronidazole SE
gi, seizures, pancreatits rare, DARK URINE
-
DIs
ETOH: disulfram-like reaction
-
Metronidazole: renal dosing
only if <10 ml/mind
-
Tetracyclines: Doxycycline, tetracycline, Minocycline MOA
binds to 30s ribosomal subunit to inhibit bacterial protein synthesis - not used as much anymore
-
Doxycycline used for:
output tx of CAP
-
Tetracyclines can be used to tx
acne
-
Quinupristin/Dalfopristin (SYnercid) MOA
inhibits protein synthesis
-
Quinupristin/Dalfopristin (SYnercid) coverage that differs from Linezolid (Zyvox)
only entercoccus faccium
-
Quinpristine/Dalfopristin SE
increase bilirubin, infusion rxn, myalgia/arthlalgia
-
Quinpristine/Dalfopristin DI
CYP3A4 inhibitor
-
Linezolid SE
thrombocytopenia, GI, CNS
-
Linezolid DI
- weak MAOI - PPA or sudafen (HTN, SSRI, TCAs (SS) - Tramadol
-
Cyclic Lipopeptides: Daptomycin - MOA
binds to bacterial membrane, causes rapid depolarization of membrane potential
-
Daptomycin DI & FDA Indication
few DIs, not hepatically metabolized - complicated skin & skin-structure infections (CSSSIs)
-
Daptomycin - renal dosage
>30 = 4mg/kg IV q 24h - < 30 ml/min: 4 mg/kd IV q 58
-
Daptomycin AE
constipation, di, vomiting, CPK increase = peg cat B
|
|